Bankrupt DNA testing company 23andMe Holding (OTC:MEHCQ) is set to hold a second auction to sell its assets, including ...

Me is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, ...

Bankrupt genetic analysis company 23andMe will hold a second auction for its cache of DNA data with an opening bid of $305 ...

Me has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

The judge overseeing the bankruptcy of 23andMe questioned the limits proposed for a second auction that is designed to push ...

The move marks a turning point in 23andMe’s tumultuous decline. Founded in 2006 by Wojcicki, the company initially gained traction with its saliva-based ancestry kits and went public in 2021. By the ...

Bankrupt genetic testing company 23andMe told a U.S. bankruptcy judge on Wednesday that it wants to re-open bidding on its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A class action lawsuit, resignations, and layoffs plagued 23andMe, which filed for Chapter 11 in March. Biotech company Regeneron is buying the DNA testing startup's assets for $256 million.

Still, it's been a rough time for 23andMe and its users over the past few years. The company had a major data breach, saw its valuation plummet, and is now ultimately bankrupted and up for sale.

Following its Chapter 11 filing in a Missouri bankruptcy court in March, South San Francisco, California-based 23andMe (OTC:MEHCQ) picked Regeneron (NASDAQ:REGN) as the successful bidder in the ...